New pill for rheumatoid arthritis passes first safety check in small study

NCT ID NCT05858788

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This early-stage study tested a new oral drug called SAR441566 in 10 healthy Japanese men to see how safe it is and how the body processes it. The drug is being developed for rheumatoid arthritis, an autoimmune disease that causes joint pain and swelling. The study only looked at safety and drug levels in the blood, not whether it actually treats arthritis.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

SAR441566 (oral tablet)

What this could lead to

If successful, this could lead to a new oral treatment option for rheumatoid arthritis, helping control the disease with fewer side effects.

What could go wrong

This is a very early Phase 1 study in only 10 healthy men, not patients. It only checks safety and drug levels, not whether it works for arthritis. Many drugs fail in later trials.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RHEUMATOID ARTHRITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

rheumatoid arthritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Parexel International-Site Number:8400001

    Glendale, California, 91206, United States